The patent protects against compounded, unapproved copies of Mitosol, the company's flagship medication, in future applications
Mitosol (mitomycin for solution) 0.2 mg/vial, Kit for Ophthalmic Use. (Credit: PRNewsfoto/Mobius Therapeutics, LLC)
Mobius Therapeutics, a US-based perioperative ophthalmic pharmaceutical firm, has received US Patent #11,540,977, Injection Apparatus and Method of Use for its injected ophthalmic Mitomycin-C.
The patent protects against compounded, unapproved copies of Mitosol, the company’s flagship medication, in future applications. Besides, the patent will support regulatory guidance, compliance, and clinical technique, said the company.
Mobius Therapeutics CEO Ed Timm said: “This is an important addition to Mobius’ IP portfolio. As the gold standard for ophthalmic mitomycin, this patent acknowledges the novelty and merits inherent to Mitosol.
“It protects the apparatus itself, its unique ability to protect healthcare workers, and its ultimate flexibility in accommodating all clinical needs.”
Mitosol is claimed as the only US Food and Drug Administration (FDA)-approved formulation of mitomycin-c with an ophthalmic indication.
The drug is said to give providers flexibility due to its shelf-ready designation, which allows for on-demand use. With room-temperature storage, the drug has a shelf life of up to 24 months, and USP <800> compliance.
Timm added: “Ophthalmic surgeons are smart and resourceful physicians, relentlessly advancing clinical excellence with improved clinical technique.
“Mobius shares this passion; franchise protection provides the resources required to respond with products to meet and exceed these demanding needs, now and into the future. In the end, everyone wins: the patient, the provider, and the American healthcare system.”
Mobius Therapeutics develops sterile perioperative ophthalmic pharmaceuticals. The firm has an additional perioperative formulation in commercialisation and an active product pipeline.